2019 American Transplant Congress
The Reduced Tacrolimus Metabolism Rate and Its Association with Estimated Glomerular Filtration Rate and Interstitial Fibrosis: A Study Using Korean Organ Transplantation Registry (KOTRY) Dataset
*Purpose: Tacrolimus is the key drug in clinical transplant, which has narrow therapeutic index. A few studies reported the association of tacrolimus metabolism rate with…2019 American Transplant Congress
Evaluation of Mycophenolate Mofetil Exposure in Renal Transplant Recipients
*Purpose: Mycophenolate mofetil (MMF) is the most commonly prescribed immunosuppressant following transplantation in the United States. However, the occurrence of MMF therapy-related adverse events including…2019 American Transplant Congress
Retrospective Nested Case Control Study of the Impact of Immunosuppression on Post Transplant Malignancy among Adult Heart Transplant Patients
*Purpose: Post-transplant malignancy is diagnosed in approximately 18% of heart transplant (HTx) recipients and is a leading long-term cause of death among these patients. The…2019 American Transplant Congress
Development and Validation of a Capillary Blood Mitra-Based Assay for the Quantitative Determination of Advagraf® Concentrations in Transplant Patients
*Purpose: Therapeutic drug monitoring of tacrolimus (TAC) requires venepuncture blood samples taken by specialists, requiring patients to attend an outpatient clinic; this can be inconvenient…2018 American Transplant Congress
Evaluation of Clinical and Safety Outcomes Following Uncontrolled Tacrolimus Conversion in Adult Transplant Recipients
Background: Long-term studies with control groups are required to assess tacrolimus (TAC) conversion. The purpose of this study was to compare clinical and safety outcomes…2018 American Transplant Congress
Tacrolimus Metabolism in Subjects with Potentially Absent CYP3A Activity
Purpose: Tacrolimus (TAC) is a well-known cytochrome P450 (CYP) 3A4 and 3A5 substrate. Common single nucleotide polymorphisms (SNPs) in these genes are significantly related to…2018 American Transplant Congress
Tacrolimus Pharmacokinetics (PK) at Low, Medium, and High Trough Levels in Patients Converted from Twice-Daily Immediate-Release Tacrolimus (TacBID) to Once-Daily Extended-Release Tacrolimus (LCPT)
LCPT (Envarsus XR®) is a once-daily, extended-release formulation of tacrolimus which has demonstrated greater bioavailability and a smoother PK profile compared to TacBID. This post-hoc…2018 American Transplant Congress
Association of CYP3A5*3*6*7 Metabolic Composites to Tacrolimus Pharmacokinetics in African American and Caucasian Renal Transplant Recipients
Background: Interpatient variability in tacrolimus pharmacokinetics(PK) is due primarily to metabolism by cytochrome P-450 3A5(CYP3A5) isoenzymes. African Americans(AA) require higher tacrolimus doses to achieve comparable…2018 American Transplant Congress
The Providers Can't Let Go! An Analysis of an RN Driven Tacrolimus Dose Adjustment Protocol
Introduction: Tacrolimus (FK) dose adjustment is frequently performed by non-MD staff. Standard protocols to evaluate the ability of non-providers to maintain pts within a goal…2018 American Transplant Congress
Institution-Based, Pharmacist-Managed Anticoagulation in Patients with a Left Ventricular Assist Device
Long-term anticoagulation with warfarin is required for patients with left ventricular assist devices (LVADs). There is limited data of time in therapeutic range (TTR) in…
- « Previous Page
- 1
- …
- 4
- 5
- 6
- 7
- 8
- …
- 12
- Next Page »